Osteoporosis Management with Sequential Therapy

Introduction to Sequential Therapy

• The American College of Rheumatology recommends that sequential therapy is mandatory after discontinuing denosumab, romosozumab, and PTH/PTHrP analogs to prevent rebound bone loss and vertebral fractures 1, 2

Critical Principle: Which Medications Require Sequential Therapy

• Denosumab strongly requires transition to bisphosphonate or romosozumab 6-9 months after the last dose to prevent rebound vertebral fractures 3, 4, 5, 6
• Romosozumab must be followed by bisphosphonate or denosumab after completing the 12-month course 1, 2, 7
• PTH/PTHrP analogs should be followed by bisphosphonate or denosumab to prevent gradual bone loss over 12-18 months 3, 4, 5, 6

Medications That Do Not Require Sequential Therapy

• Bisphosphonates can be discontinued without sequential therapy 4, 5, 6
• Raloxifene can be discontinued without sequential therapy 4, 5, 6

Specific Sequential Therapy Algorithms

• After denosumab discontinuation, start bisphosphonate 6-9 months after the last dose 3, 4, 5, 6
• After PTH/PTHrP discontinuation, transition to bisphosphonate or denosumab immediately after completing the course 3, 4, 5, 6
• After romosozumab discontinuation, transition to bisphosphonate or denosumab after the 12-month course 1, 2, 3, 7

Treatment Failure Requiring Sequential Change

• If osteoporotic fracture occurs ≥12 months after starting therapy or significant BMD loss after 1-2 years, switch to a different medication class 4
• From oral bisphosphonate, switch to IV bisphosphonate, denosumab, romosozumab, or PTH/PTHrP if poor adherence/absorption is suspected 4

Special Considerations for Glucocorticoid-Induced Osteoporosis

• Anabolic agents are conditionally recommended as initial therapy over antiresorptives for very high fracture risk patients 1, 2, 8
• Very high risk is defined as prior osteoporotic fracture(s) or BMD t-score ≤-3.5 or FRAX 10-year risk of major osteoporotic fracture ≥30% or hip ≥4.5% or high glucocorticoid dose ≥30 mg/day for >30 days or cumulative doses ≥5 g/year 3

Common Pitfalls to Avoid

• Never stop denosumab without planning sequential bisphosphonate therapy, as this is associated with rapid bone loss and vertebral fractures 3, 4, 5, 6
• Never transition from denosumab to PTH/PTHrP, as this causes transient bone losses 4
• Never use romosozumab beyond 12 months, as the anabolic effect wanes 7